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Background: To identify distinct groups of patients with fibromyalgia (FM) with respect to multiple outcome
measures.
Methods: Data from 631 duloxetine-treated women in 4 randomized, placebo-controlled trials were included in a
cluster analysis based on outcomes after up to 12 weeks of treatment. Corresponding classification rules were
constructed using a classification tree method. Probabilities for transitioning from baseline to Week 12 category
were estimated for placebo and duloxetine patients (Ntotal = 1188) using logistic regression.
Results: Five clusters were identified, from “worst” (high pain levels and severe mental/physical impairment) to
“best” (low pain levels and nearly normal mental/physical function). For patients with moderate overall severity,
mental and physical symptoms were less correlated, resulting in 2 distinct clusters based on these 2 symptom
domains. Three key variables with threshold values were identified for classification of patients: Brief Pain Inventory
(BPI) pain interference overall scores of <3.29 and <7.14, respectively, a Fibromyalgia Impact Questionnaire (FIQ)
interference with work score of <2, and an FIQ depression score of ≥5. Patient characteristics and frequencies per
baseline category were similar between treatments; >80% of patients were in the 3 worst categories. Duloxetine
patients were significantly more likely to improve after 12 weeks than placebo patients. A sustained effect was seen
with continued duloxetine treatment.
Conclusions: FM patients are heterogeneous and can be classified into distinct subgroups by simple descriptive
rules derived from only 3 variables, which may guide individual patient management. Duloxetine showed higher
improvement rates than placebo and had a sustained effect beyond 12 weeks.
Keywords: Fibromyalgia, Duloxetine, Cluster analysis, Patient subgroups, PredictionBackground
Fibromyalgia (FM) has been defined by the American
College of Rheumatology (ACR) as pain in all 4 quad-
rants and axial skeletal pain, together with at least 11 of
18 tender point sites (1990 ACR criteria [1]), although
revised criteria are being proposed [2], and new preli-
minary diagnostic criteria for FM were published in
2010 [3]. About 2% of the US general population suffers
from FM. Patients often also suffer from concomitant
symptoms such as fatigue, headache, and sleep distur-
bance [3]. Mood disorders are also commonly diagnosed
in these patients with approximately 25% to 40% of FM* Correspondence: sagmand@lilly.com
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unless otherwise stated.patients reporting symptoms of current major depressive
disorder (MDD) [4,5].
Fibromyalgia symptoms may be in part due to defi-
ciencies in serotonin (5-HT) and norepinephrine (NE), 2
neurotransmitters that have been implicated in the
mediation of endogenous analgesic mechanisms via the
descending inhibitory pain pathways in the brain and
spinal cord [6,7]. Recent evidence suggests that in patho-
logical pain states, these endogenous pain inhibitory
mechanisms may be dysfunctional. An imbalance in
these inhibitory mechanisms may contribute to the cen-
tral sensitization and hyperexcitability of the spinal and
supraspinal pain transmitting pathways, and may manifest
as persistent/chronic pain [8]. These mechanisms of
central sensitization and inhibition of the descending
anti-nociceptive pathways due to a diminished availabilityral. This is an Open Access article distributed under the terms of the Creative
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genesis of FM [9-11].
Duloxetine hydrochloride, hereafter referred to as duloxe-
tine, is a potent, selective, and balanced serotonin and nor-
epinephrine reuptake inhibitor (SNRI) in vitro and in vivo.
It is approved by the Food and Drug Administration for the
treatment of MDD [12,13], generalized anxiety disorder
[12,14], FM [15,16], diabetic peripheral neuropathic pain
[17,18], and chronic musculoskeletal pain [17]. With its
dual reuptake activity achieved at the recommended dose
of 60 mg/day (with minimal or no titration), duloxetine
has a relatively early onset of action both in terms of pain
and mood components of FM. Duloxetine’s analgesic ef-
fects in the supraspinal and descending inhibitory spinal
pain pathways are essentially independent of its central
antidepressant effects, explaining perhaps its therapeutic
effect in distinct mood and pain syndromes as well as syn-
dromes with considerable co-morbidity, such as FM.
In one Phase II study and three Phase III studies, pa-
tients with FM (with or without MDD) were effectively
treated with duloxetine in various doses compared to
placebo [4,5,16,19]. An additional Phase III study eva-
luated the safety and tolerability of duloxetine during an
extended period of up to 60 weeks and showed that
long-term treatment is safe and well tolerated [20,21].
Results in these studies have been described mainly in
terms of average scores and mean changes on different
symptom and functioning rating scales. Following on
from previous studies that examined subgroups of FM
patients [21,22], and to obtain a better understanding of
the frequency and extent of changes at an individual pa-
tient level, we used data from these registration studies
in a cluster analysis to identify distinct subgroups of FM
patients based on measures of pain, mental and physical
impairment, global impression, and overall functioning.
Descriptive rules were derived to classify patients into
outcome categories in terms of their overall health sta-
tus. The relationship between and relative importance of
the pain, mood, and functioning domains in FM were
also explored. Finally, changes in outcome categories
over time were examined in an attempt to predict re-
sponse after treatment with duloxetine, depending on
patient characteristics at the start of treatment.
Methods
Data sets
Data from the 4 randomized, parallel, double-blind,
placebo-controlled studies in FM, according to the 1990
ACR criteria [1], were included [4,5,16,19]. These studies
had similar inclusion and exclusion criteria and com-
pared the effects of duloxetine against placebo in a total
of 1,276 FM patients with or without MDD. Treatment
duration varied between 12 and 58 weeks. Consequently,
the last available score within the time interval from 2 to12 weeks after baseline was used as outcome for the
cluster analysis. Patients treated with duloxetine received
doses of 30 mg once daily (QD) or twice daily (BID),
60 mg QD or BID, or 120 mg QD.
A fifth study in comparable FM patients [20], designed
as a long-term safety study of duloxetine at doses of 60
and 120 mg QD, was used to assess long-term changes.
All evaluated studies were approved by the applicable
Ethical Review Boards and conducted in line with Good
Clinical Practice (according to International Conference
on Harmonisation) and the Declaration of Helsinki. All
patients provided their informed consent to participate
in the study prior to any study procedures.
Scales and assessments
Clusters were identified by measures of pain, mental and
physical impairment (including fatigue), global impres-
sion, and overall functioning. A total of 18 outcome va-
riables from the following scales were used:
 Pain: Brief Pain Inventory (BPI) (overall score for
pain interference and average pain intensity) [23]
and item 15 (pain) of the Fibromyalgia Impact
Questionnaire (FIQ) [24].
 Mental impairment: mental composite summary
score of the 36-item short form questionnaire
(SF-36) [25], Beck Depression Inventory (BDI) total
score [26], and FIQ items 19 (anxiety) and 20
(depression).
 Physical impairment: FIQ physical impairment
subscore (average of FIQ items 1–11, multiplied by
3.33 to obtain a score between 0 and 10), FIQ items
14 (interference with work) and 16–18 (tiredness,
awoke rested, and stiffness, respectively), and SF-36
physical composite summary score.
 Global impression: Patient Global Impression of
Improvement (PGI-I) and the Clinician Global
Impression of Severity (CGI-S) [27].
 Overall functioning: Sheehan Disability Scale (SDS)
assessing global disability in 3 areas: work, social life,
and family life [28].
BPI pain interference and average pain intensity, FIQ
items, and the areas of the SDS are rated on an 11-point
scale ranging from 0 (best) to 10 (worst). PGI-I and
CGI-S are scored on a 7-point scale from 1 (best) to 7
(worst). BDI items are rated on a 4-point scale from 0
(best) to 3 (worst); the BDI total score ranges from 0
(best) to 63 (worst). Thus, higher scores indicate a more
negative impact for these scales. The SF-36 mental and
physical composite summary scores were derived by
principal component analysis [29]; higher SF-36 scores
indicate better health status or functioning (ranges: men-
tal composite summary score from −1.3 [worst] to 80.7
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[worst] to 76.3 [best]).
Except for BDI, all scales were used in all 4 placebo-
controlled studies. For the one study with no BDI data
[5], BDI scores were estimated by linear regression
analysis applied on Hamilton Depression Rating Scale
(HAMD) items [30]. In the long-term safety study, all
scales except for the SF-36 were employed.
Statistical methods
Cluster analysis
In a first step, a cluster analysis was performed on all
female patients to identify distinct groups of patients
characterized by the outcomes described above after up
to 12 weeks of duloxetine treatment. Following trans-
formation of values into z-scores, a k-means clustering
algorithm in JMP 6.0.2 software was applied to the data
on the 18 outcome measures [31]. Clustering of multi-
variate data was visualized using a 2-dimensional biplot
projection of patients and outcomes [32].
A heuristic approach was used to decide on the number
of clusters, based on the reproducibility of clustering
across different numbers of clusters. The stability (repro-
ducibility) was evaluated by randomly dividing the dataset
into 2 halves and applying the k-means procedure to both
halves separately. The agreement between the two parti-
tions was then evaluated using the adjusted Rand index
[33]. The average index computed over 500 random data
splits was plotted against the number of clusters to
identify the number of clusters above which there was a
substantial drop in reproducibility.
To confirm the outcome of this approach, an alter-
native procedure was applied, the theoretically validated
JUMP method (available at http://www-rcf.usc.edu/~gareth/
research/jump, with documentation at http://www-bcf.usc.
edu/~gareth/research/jumpdoc.pdf) [34].
Identification and application of descriptive rules
In the next step, a classification tree algorithm was ap-
plied to the same data to derive descriptive rules that
would allow the classification of a patient into outcome
categories that mimic the identified clusters. The out-
come variable was the class membership and the pre-
dictor variables were the same variables that were used
in the clustering procedure. However, the SF-36 mental
and physical composite summary scores were excluded
so that these results could be projected on the long-term
safety study in which the SF-36 was not employed. The
algorithm, similar to the Classification and Regression
Trees (CART) algorithm introduced by Breiman et al. in
[35], sequentially splits data into 2 child subsets by choo-
sing the best cut-off point from all available variables so as
to make the resulting 2 subsets as “pure” as possible in
terms of their class memberships. Specifically, a recursivepartitioning algorithm available in the Partition platform
of the JMP 6.0.2 software was used. The descriptive rules
were then constructed for each outcome cluster by follo-
wing the splits leading to the nodes of the tree that were
most representative of that cluster.
The descriptive rules were then applied to all patients
with available data, including patients treated with pla-
cebo, and at baseline and the 12-week endpoint.
Evaluation of probabilities for transitioning from baseline
to endpoint categories
Shift tables for transitioning from baseline to endpoint
categories were generated and frequencies compared bet-
ween duloxetine and placebo. Switching probabilities were
modeled in a multinomial logistic regression analysis that
included categorical factors for baseline category, treat-
ment, treatment by baseline category interaction and
other baseline covariates (age, race, previous antidepres-
sant use, body mass index [BMI], diagnosis of MDD)
using SAS proc LOGISTIC. Stepwise variable selection
was used to select relevant baseline covariates. The
general form of the multinomial logistic model for k out-
come categories with logit link function was used. This
allowed estimation of the probability of switching from
any baseline category to any specific outcome category,
for a given treatment group and other covariates included
in the logistic regression. The confidence intervals for the
difference in switching probabilities across treatment
groups and associated p-values were computed using proc
NLMIXED.
Assessment of the long-term effect of duloxetine using
categories
To assess the long-term effect of duloxetine, patients
from the long-term safety study were categorized ac-
cording to the descriptive rules identified in previous
procedures using available data from Week 14 (LOCF
interval: >Week 1 to Week 14) and Week 26 (LOCF
interval: >Week 19 to Week 26). Similarly, as a supporting
analysis, patient frequencies per category were computed
for 2 of the 4 studies used in the cluster analysis that in-
cluded an extension phase. A similar LOCF approach as
for the long-term safety study was applied.
Results
Demographics and baseline characteristics
In the 4 studies included, a total of 1,253 patients had
non-missing BPI and FIQ outcome scores after at least
2 weeks of treatment; 1,188 women and 65 men. Since the
number of men was considered too low to draw reliable
conclusions, only women were included in the analyses.
Of these 1,188 women 724 were treated with duloxetine
and 464 randomized to placebo. No relevant differences
between treatment groups in demographics and baseline
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(SD) age was 50.3 (11.0) years, 86.8% were Caucasian and
9.7% Hispanic, and mean (SD) BMI was 29.8 (7.0) kg/m2.
A major depressive episode was present in 26.9% of pa-
tients and 47.4% had previously received antidepressants.
Cluster analysis
The initial cluster analysis was performed based on 631
duloxetine treated female patients who had non-missing
scores for all 18 variables after at least 2 weeks of treat-
ment. The k-means procedure with the number of clus-
ters set as 4, 5, and 6 resulted in the selection of k = 5,
leading to reasonably robust, i.e. reproducible, results.
This number of clusters was also suggested by the JUMP
procedure [34]. Furthermore, this choice of k turned out
to be the most appropriate from a medical perspectiveTable 1 Mean scores and percent of patients meeting sds rem
Variable Scale Cluster 1
(worst), (p
N = 78
Pain
BPI - Average pain intensity BPIAVP 7.58
BPI - Pain interference (overall score) BPIPIF 7.89
FIQ item 15: Pain FIQ15 8.71
Mental impairment
FIQ item 19: Anxiety FIQ19 7.38
FIQ item 20: Depression FIQ20 6.91
BDI total score BDI 25.08
SF-36 mental composite summary score SF36M 34.46
Physical impairment
FIQ - Physical impairment FIQPI 6.77
FIQ item 14: Interference with work FIQ14 8.26
FIQ item 16: Tiredness FIQ16 9.18
FIQ item 17: Awoke rested FIQ17 9.19
FIQ item 18: Stiffness FIQ18 8.79
SF-36 physical composite summary score SF36P 24.88
Global impression
CGI-S CGIS 4.35
PGI-I PGII 4.27
Overall functioning
SDS - Work/school SDS1 8.01
SDS - Social life SDS2 7.64
SDS - Family SDS3 7.82
SDS – Overall SDS 23.5
SDS – Overall ≤6 (%) (remission criterion) 0.0
BDI = Beck Depression Inventory; BPI = Brief Pain Inventory; CGI-S = Clinician Global
of patients with available data; PGI-I = Patient Global Impression of Improvement; S
Note: for SF-36 scores, the higher the score the better the patient’s well-being, whilwith distinct characteristics per cluster. Table 1 presents
the mean scores at Week 12 per identified cluster for
each of the included scales and Figure 1 a projection
graph (biplot) of the 5 clusters.
Based on these results, patients in Cluster 1 (“worst”
cluster) are characterized by high pain levels and severe
mental and physical impairment as shown by worst
mean outcome scores in all examined areas (Table 1).
Patients in Cluster 2 (“physically poor”) have high pain
levels and high physical impairment, whereas patients in
Cluster 3 (“mentally poor”) have moderate pain levels
and high mental impairment. Patients in Cluster 4
(“moderate”) have considerably improved scores in all
areas compared to Clusters 1–3 and are characterized by
moderate levels of pain or mental/physical impairment.
Mean scores for Cluster 5 (“best”) were further markedlyission criterion by cluster at 12 weeks
Mean score
Cluster 2
hysically poor),
Cluster 3
(mentally poor),
Cluster 4
(moderate),
Cluster 5
(best),
N = 135 N = 104 N = 185 N = 129
5.93 4.12 3.55 1.43
4.77 4.21 2.23 0.60
7.03 5.03 4.42 1.70
2.30 5.09 1.70 0.67
1.45 5.09 1.12 0.57
7.93 15.81 5.99 3.46
53.70 37.31 54.08 56.37
4.42 4.55 2.56 1.23
6.29 4.82 3.16 0.77
7.82 7.31 5.88 2.28
7.66 7.08 5.66 2.46
6.87 5.69 4.58 1.88
24.51 32.77 34.13 45.90
3.80 3.50 3.01 2.18
3.61 2.97 2.63 1.57
5.66 5.06 2.55 0.87
5.26 5.36 2.07 0.73
5.59 5.33 2.38 0.83
16.5 15.7 7.00 2.43
1.48 2.88 46.0 90.7
Impression of Severity; FIQ = Fibromyalgia Impact Questionnaire; N = Number
F-36 = 36-item short form questionnaire; SDS = Sheehan Disability Scale.
e for all other scores, the higher the score the worse the patient’s well-being.
Figure 1 Cluster analysis results projected on a biplot. BDI = Beck Depression Inventory; BPIAVP = Brief Pain Inventory - average pain intensity;
BPIPIF = Brief Pain Inventory - pain interference score; CGIS = Clinician Global Impression of Severity; FIQPI = Fibromyalgia Impact Questionnaire
physical impairment; FIQx = Fibromyalgia Impact Questionnaire item x; PGII = Patient Global Impression of Improvement; SF36M = 36-item short
form questionnaire – mental composite summary score; SF36P = 36-item short form questionnaire – physical composite summary score; SDSx = Sheehan
Disability Scale domain x. Note: Symbols indicate patients, rays indicate outcome variables. Angles between rays reflect the degree of association between
variables: variables that are highly related would be shown as co-directional rays (if positively correlated) or anti-directional (if negatively correlated);
coordinates for patients are based on the first 2 principal components and, for the outcomes, on the loadings of individual variables on the principal
components. Patients with similar outcomes are grouped together in the multivariate space which agrees with the class memberships from cluster
analysis, indicated by color and symbol. Numbers in boxes indicate the centers of the respective cluster. The point at the intersection of the axes is
associated with a hypothetical patient having average scores for all outcomes.
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and physical status, reflecting a condition close to what
one might expect in the general population. Outcome
Clusters 1 and 3 had the highest proportion of patients
with concomitant MDD at baseline – 53.9% and 39.4%,
respectively; this proportion was lower in Cluster 5
(24.0%) and lowest in Clusters 2 (16.3%) and 4 (18.9%).
The clusters can also be interpreted in terms of the pro-
portion of patients meeting the Sheehan Disability Scale
remission criterion (SDS overall ≤6). Consistent with
general interpretation of the clusters, the percent of pa-
tients meeting the SDS remission criterion was very low
(<3%) in Clusters 1, 2, and 3, but reached 46% in Cluster
4 and >90% in Cluster 5 (Table 1).Categories and descriptive rules
In the next step, a classification tree recursive partition-
ing algorithm was applied on the same data in order toidentify categories that mimic the clusters in terms of
patient characteristics.
As shown in Figure 2, the following 3 key variables
and corresponding threshold values were identified:
BPI pain interference overall scores (BPIPIF) of <3.29
and <7.14, respectively, an FIQ interference with work
(FIQ14) score of <2, and an FIQ depression (FIQ20)
score of ≥5. According to these variables and threshold
values, simple descriptive rules for each category were
defined allowing individual patients to be classified into
any of the 5 categories. Within each resulting category,
the majority of patients (60% to 88%) were from the cor-
responding cluster.
The accuracy of the approximation of the categories to
the clusters was assessed with the area under the re-
ceiver operating characteristic (ROC) curve, which was
at least 82% for each of the 5 clusters. This indicated a
good approximation with reasonable accuracy despite
the limited number of variables included.
Figure 2 Describing outcome clusters using a classification tree. BPIPIF = Brief Pain Inventory (BPI) pain interference overall score;
FIQ14 = Fibromyalgia Impact Questionnaire (FIQ) interference with work score; FIQ20 = FIQ depression score; N = Number of patients with
available data who were also included in the cluster analysis.
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the 5 outcome categories, and the respective classifica-
tion of duloxetine and placebo group patients of the 4
studies at baseline and 12 weeks.
Frequencies were similar between treatment groups at
baseline. The majority of patients (>80%) at baseline
belonged to the 3 worst categories 1 (worst), 2 (physicallyBaseline
Duloxetine
N=726
Placebo
N=466
Dulox
N=7
N
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N  =  number of evaluable patients at basel
Figure 3 Frequencies of patients per category at baseline and week 1
Category 1: BPIPIF ≥7.14; Category 2: 3.29≤ BPIPIF <7.14 AND FIQ20 < 5; Catego
FIQ14≥ 2, Category 5: BPIPIF <3.29 AND FIQ14 < 2. BPIPIF = BPI pain interferenc
observation carried forward; N = Number of evaluable patients with outcome dpoor), and 3 (mentally poor), and only about 15% were in
the 2 best categories. After 12 weeks of treatment, about
half of patients in the duloxetine group (51.6%) compared
to 35.6% of the placebo group were in the 2 best catego-
ries 4 (moderate) and 5 (best), with reductions in frequen-
cies primarily observed in categories 1 and 3 (Figure 3).
Specifically, the proportion of patients in these 2Endpoint
Category 1 (Worst)
Category 2 (Phys. poor)
Category 3 (Ment. poor)
Category 4 (Moderate)
Category 5 (Best)
etine
27
Placebo
N=472
ine and endpoint (Week 2-12, LOCF) 
2. Definition of categories, based on the classification rules from Figure 2:
ry 3: 3.29≤ BPIPIF <7.14 AND FIQ20≥ 5; Category 4: BPIPIF <3.29 AND
e overall scores; FIQ = Fibromyalgia Impact Questionnaire; LOCF = last
ata at baseline and endpoint (Week 2–12, LOCF).
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duloxetine group and from 61.4% to 44.1% (-17.3%) in the
placebo group.
Probabilities for transitioning from baseline to week 12
category
Probabilities for changes in category from baseline to
Week 12 were estimated using a logistic regression of the
data set, excluding the few subjects with missing or best
(5) baseline category or with missing outcome category
(see Table 2 and Figure 4). For each of the poorer baseline
categories, more patients treated with duloxetine than with
placebo improved to a better category during the 12-week
period. Whereas more than 10% of patients in either treat-
ment group (12.8% and 10.8%, respectively) deteriorated
from the “mentally poor” category to the “worst” category,
only 2.9% and 6.0% of patients, respectively, in the “physic-
ally poor” category deteriorated to the “worst” category.
For all but 1 category changes representing an improve-
ment, frequencies were higher in the duloxetine group
than in the placebo group (statistically significant for 5
such changes as indicated in Table 2 and Figure 4). For the
change from category 2 (physically poor) to category 3
(mentally poor), the frequency was significantly higher in
the placebo group than in the duloxetine group, which is
due to more duloxetine patients having shifted from cat-
egory 2 to categories 4 and 5 (Table 2 and Figure 4).
To evaluate the impact of potential baseline covariates
other than the baseline category (age, race, current de-
pression status, and previous antidepressant use) on the
probability of different outcome category membership,
a stepwise variable selection was performed within each
treatment group using the same multinomial logistic re-
gression model (see statistical methods section). Over-
all, after adjusting for multiplicity, none of the available
baseline predictors was seen to substantially improve
the prediction model, once the baseline category was
included in the model. As weak evidence, we report that
within the duloxetine group, “previous antidepressant
use” appeared to decrease the likelihood of the worst
outcome compared to all other categories (overall
p = 0.046).Table 2 Relative frequencies for transitioning from baseline t
Percentage of patients (duloxetine/placebo)
Endpoint ca
Baseline category 1 (worst) 2 (physically poor) 3 (ment
1 (worst) 27.5/42.5** 25.8/17.2* 16.6
2 (physically poor) 2.9/6.0 30.5/41.7* 7.1/
3 (mentally poor) 12.8/10.8 20.6/24.3 13.5/
4 (moderate) 2.2/3.2 20.4/16.1 3.2
Total no. of patients 90/80 180/123 77
*p < 0.05, **p < 0.01 for the between-treatment difference in the incidence of transiLong-term Effect of Duloxetine
As a sensitivity analysis to assess the changes over a lon-
ger period of time, the descriptive rules were applied on
the open-label long-term safety study in which patients
received duloxetine for up to 62 weeks [20]. Table 3
summarizes the frequencies for switching categories
from Week 14 to Week 26. The vast majority of patients
either maintained or improved their category; even in
the “best” category, 74.3% of patients maintained their
status at Week 26 compared to Week 14.
A similar analysis was performed on 2 of the 4 studies
used in the cluster analysis that included an extension
phase. Again, more than 70% of patients who had
reached the best category at Week 12/13 (depending on
the study) were able to maintain their good health con-
dition and thus stay in Category 5 at Week 27/28, after
another 15 weeks of duloxetine treatment.
Discussion
Since FM is a complex and heterogeneous condition, the
European League against Rheumatism (EULAR) recom-
mends a comprehensive assessment of pain, function,
and psychosocial context [36]. One main goal of the
pooled analysis presented here was to support the vali-
dity of distinct subgroups of FM patients suggested by
previous cross-sectional studies. We also explored the
usefulness of these subgroups for the clinician in posi-
tioning the FM patient along the spectrum of different
symptom and functioning domains and in predicting
outcome and differential response to treatment, which
may provide guidance on the level and type of care and
support for the patient’s needs.
One major difference between this analysis and pre-
vious studies of FM patients [22,37,38] is that the
clustering was not based on patient characteristics at
baseline but on a wide range of post-baseline efficacy
measures collected after 12 weeks of treatment with
duloxetine. This allowed the definition of the “best”
Cluster 5 that included patients with low pain levels and
nearly normal mental and physical status.
Cluster 5 reflects a pronounced positive development
over time such that patients in this cluster seem to beo endpoint category
tegory
ally poor) 4 (moderate) 5 (best) Total no. of patients
/22.4 21.0/9.7** 9.2/8.2 229/134
17.2** 36.4/25.8* 23.0/9.3** 239/151
30.6** 36.2/24.3* 17.0/9.9 141/111
/8.1 41.9/50.0 32.3/22.6 93/62
/95 225/110 130/50 702/458
tioning.
Baseline category:
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Category 1 (Worst) Category 2 (Phys. poor) Category 3 (Ment. poor)
Category 4 (Moderate) Category 5 (Best)
1 2 3 4
N
um
be
r 
of
 p
at
ie
nt
s 
(%
) 
pe
r 
en
dp
oi
nt
 c
at
eg
or
y
229Number of patients: 239 141 93134 151 111 62
**
*
**
*
**
*
*
**
DLX    PLC DLX    PLC
**
DLX    PLC DLX    PLC
Figure 4 Relative frequencies for transitioning from baseline to endpoint category. The stacked bars show the distribution of patients
from a given baseline category into 5 endpoint categories. The categories, based on the classification rules from Figure 2. (Category 1: BPIPIF
≥7.14; Category 2: 3.29 ≤ BPIPIF <7.14 AND FIQ20 < 5; Category 3: 3.29≤ BPIPIF <7.14 AND FIQ20≥ 5; Category 4: BPIPIF <3.29 AND FIQ14 ≥ 2,
Category 5: BPIPIF <3.29 AND FIQ14 < 2). *p < 0.05, **p < 0.01 for the between-treatment difference in the probability of transitioning from a
baseline category to the endpoint category. Note: Data from category 5 at baseline were excluded because only 20 duloxetine and 7 placebo
patients fulfilled criteria for this category at baseline, which did not allow for any meaningful modeling and interpretation of transition probabilities.
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to some extent with the 3 subgroups of FM patients de-
scribed by Giesecke et al. [37]. Giesecke identified a
group of patients with a high severity of pain combined
with a high degree of mental impairment, which would
correspond to Cluster 1 (worst) in the present analysis,
and a group with a moderate degree of these symptom
domains, similar to Cluster 4 (moderate). The third,
smaller group identified by Giesecke et al. included pa-
tients with a low degree of mood disturbances but with
a high tenderness on evoked pain testing, which might
overlap to some extent with our Cluster 2 (physically
poor). Our cluster analysis results differentiated between
2 distinct symptom domains characterized by either
physical impairment (Cluster 2) or mental impairment
(Cluster 3), while these 2 resulting clusters were other-
wise similar in terms of pain intensity. Similarly, based
on 3 symptom factor scores (musculoskeletal, non-
musculoskeletal, and cognitive/psychological symptoms),
Wilson et al. identified 4 clusters of FM patients whereTable 3 Relative frequencies for transitioning from week 14 t
safety study
Percentage of dulox
Category at w
Category at Week 14 1 (worst) 2 (physically poor) 3 (ment
1 (worst) 43.6 18.0 2
2 (physically poor) 7.8 28.1 2
3 (mentally poor) 18.4 15.8 4
4 (moderate) 0 23.7 1
5 (best) 5.7 8.6 2
Total number of patients 31 48Groups 2 and 3 differ with regard to more pronounced
physical and cognitive/psychological symptoms, respect-
ively, similar to our Clusters 2 and 3 [22]. De Souza
et al. emphasize anxiety and depression as a differentiat-
ing factor, based on a 2-cluster model of the FIQ items
[38]. This was confirmed in the present cluster analysis,
which differentiated between mental and pain/physical
complaints and impairments in patients situated be-
tween the worst and moderate levels of overall symptom
severity. The comparable results of these other studies
and the present findings seem to add validity to the con-
cept of distinct homogenous subgroups within the broad
range of FM patients, despite the fact that underlying
outcome measures varied between studies and a differ-
ent construct, based on post-baseline efficacy data, was
applied in the present cluster analysis.
The heterogeneity across the clusters also allowed us
to establish patient categories that approximate the clus-
ters with high sensitivity and specificity, using distinct
descriptive rules based on only 3 key outcome variableso week 26 in duloxetine patients of a long-term
etine patients
eek 26
ally poor) 4 (moderate) 5 (best) Total number of patients
3.1 12.8 2.6 39
5.0 28.1 10.9 64
7.4 10.5 7.9 38
1.9 37.3 27.1 59
.9 8.6 74.3 35
51 52 53 235
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http://www.biomedcentral.com/1471-2474/15/450(BPI pain interference; FIQ items 14 [interference with
work] and 20 [depression]). Using such rules, any given
patient can be classified into one of these categories, as
long as data on the 3 outcome variables are available. In
the present analysis, pain impact severity seemed to be
the most important parameter driving classification of a
patient into the 2 best categories or the 3 worst catego-
ries. For patients with moderate pain interference, the
level of depression was decisive for Category 2 versus 3.
For patients with low pain interference, “interference
with work” determined the split between Category 4 ver-
sus 5. These findings may help guide the clinician’s treat-
ment strategy for the individual FM patient.
The SDS has been used as a validated measure of
functional improvement and remission for patients suf-
fering from major depression and generalized anxiety
disorders [39]. In the present study, the SDS-based re-
mission criterion discriminated very well between clus-
ters with poor outcome (Clusters 1–3) and those with
better outcome (Clusters 4–5), but provided little dis-
crimination among Clusters 1–3 (Table 1). Moreover,
91% of patients in Cluster 5 achieved a functional remis-
sion based on the SDS criterion, highlighting its utility
in patients with FM.
Duloxetine and placebo were compared based on
category frequencies at baseline and after 12 weeks of
treatment, confirming the results seen in the individual
studies [4,5,16,19]. While frequencies per category were
similar between treatment groups at baseline, more
duloxetine than placebo patients fell into the 2 best cate-
gories after 12 weeks. This was confirmed in the analysis
of transition probabilities.
Mentally poor patients (Cluster 3) were more likely to
deteriorate to Cluster 1 than physically poor patients
(Cluster 2), suggesting that mental impairment is the
more detrimental co-morbidity compared to physical
impairment influencing outcome category. Furthermore,
a better treatment effect on the change in categories
from baseline to Week 12 was observed in physically im-
paired patients. This supports the independent analgesic
properties of duloxetine and suggests that it is a bene-
ficial treatment for FM patients, irrespective of the pre-
sence of mental impairment.
Aside from the most predictive factors, i.e. treatment
and baseline category, previous use of antidepressants
was identified as a modestly significant predictor of out-
come category. Results indicated that duloxetine-treated
patients with previous antidepressant use were doing
moderately better. However, it is not clear if duloxetine
is protecting against a history of depression and/or if it
is an indication that duloxetine as an SNRI has a positive
effect on both pain and emotional problems in FM, in
contrast to the most commonly used antidepressants, i.e.
selective serotonin reuptake inhibitors (SSRIs). Futurestudies would be needed to confirm this hypothesis in
FM, to support the literature reporting the beneficial
role of duloxetine in patients with MDD and painful
physical symptoms who were switched from failed initial
treatment with SSRIs or other SNRIs [40,41].
A sustained effect of duloxetine was seen when classi-
fication rules were applied to the long-term study. The
“best” outcome category at 14 weeks was maintained at
24 weeks in almost 75% of patients. About 64% of pa-
tients with “moderate” outcome either maintained their
status or improved to the “best” category. Considering
that the remainder of patients in this category worsened
(36%), the presence of mild residual symptoms may indi-
cate a risk for relapse. On the other hand, more than
half of the patients in the “worst” category at Week 14
were able to improve their status with duloxetine treat-
ment up to Week 26.
This cluster analysis confirms earlier findings that FM
patients are heterogeneous with different levels of im-
pairment [37,38], emphasizing the need for treatments
tailored to the individual patient while also taking into
account both the mental and physical symptoms of the
patient. Some patients with minor impairment could be
treated in primary care with advice and pharmacological
or non-pharmacological support. The more complex pa-
tients with a high level of physical and/or mental impair-
ment are better treated in tertiary care with a tailored
multidisciplinary approach, as also suggested by Van
Koulil [42,43]. According to the individual patient’s co-
morbidity, such treatment should not only focus on pain
medication, but also on education, treatment of secon-
dary depressive/anxiety disorders, functional rehabilita-
tion, and psychotherapy. A meta-analysis by Häuser
provided strong evidence that multi-component therapy
has beneficial short-term effects on the main symptoms
of FM, but has no effect in the long term [44]. Häuser
therefore underlined the need to develop strategies to
maintain a long-term benefit. This process may need to
focus on teaching self-management strategies and ad-
dressing perpetuating personality factors such as per-
fectionism, and on treating mental impairment, as this
seems to be one of the more negative prognostic factors.
Limitations of the described analyses and results were
as follows:
 Data were from registration studies. Study patients
were selected based on the respective trial’s entry
criteria, and variables were collected only in relation
to the studies’ objectives. The presented results may
therefore not be generalizable and representative for
the general FM patient population.
 The analysis included female patients only.
 An LOCF approach was applied to substitute
missing values from withdrawals, which may have
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2, and 3) because the LOCF methodology ignores
the fact that patients may have improved if they
stayed on treatment for a longer period of time or
until the study end. We conducted some additional
sensitivity analyses that demonstrated that when
LOCF outcomes are replaced with outcomes
imputed from repeated measures likelihood based
modeling (data not shown here), then patients with
poorer outcomes who discontinued early would
achieve somewhat better outcomes. However,
qualitatively, clusters were similar to those obtained
with LOCF imputation.
 The duloxetine doses administered were not
consistent and varied depending on the source study
(30 mg QD or BID, 60 mg QD or BID, or 120 mg
QD). With the general idea to assess rather broadly
the difference between placebo and duloxetine in
forming different outcome clusters different doses
had not been taken into account.
 Due to the limited availability of scales, other
domains such as personality traits or tenderness
could not be assessed.Conclusions
These analyses show that FM patients are heterogeneous
and can be classified into distinct subgroups based on
overall symptom and impairment severity, and on the
basis of the predominance of mental versus physical
symptoms for patients with intermediate overall severity
level. Treatment with duloxetine showed higher im-
provement rates than with placebo, and the majority of
patients on duloxetine in any category either maintained
or improved their health status beyond 12 weeks. The
results underline the need for further research into FM
patient subgroups and the importance of a comprehen-
sive patient assessment as a first step towards a tailored
treatment.
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